Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RYTM Stock Forecast 2026-2027
$109.69
Current Price
$7.54B
Market Cap
Buy 15
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RYTM Price Targets
+45.0%
To High Target of $159.00
+29.5%
To Median Target of $142.00
-4.3%
To Low Target of $105.00
RYTM Price Momentum
+1.2%
1 Week Change
+14.5%
1 Month Change
+21.0%
1 Year Change
+2.5%
Year-to-Date Change
-10.2%
From 52W High of $122.20
+47.2%
From 52W Low of $74.50
📊 TOP ANALYST CALLS
Did RYTM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rhythm is one of their latest high-conviction picks.
Latest RYTM Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, RYTM has a bullish consensus with a median price target of $142.00 (ranging from $105.00 to $159.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $109.69, the median forecast implies a 29.5% upside. This outlook is supported by 15 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RYTM Analyst Ratings
15
Buy
1
Hold
0
Sell
RYTM Price Target Range
Low
$105.00
Average
$142.00
High
$159.00
Current: $109.69
Latest RYTM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RYTM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Lisa Walter | Outperform | Maintains | $141.00 |
| Jun 16, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jun 15, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 7, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 6, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 6, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 20, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 20, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Mar 20, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Mar 18, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 17, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 17, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Mar 17, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Mar 17, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Mar 17, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Mar 17, 2026 | Needham | Buy | Maintains | $N/A | |
| Mar 12, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 2, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 2, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Rhythm Pharmaceuticals Inc. (RYTM) Competitors
The following stocks are similar to Rhythm based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rhythm Pharmaceuticals Inc. (RYTM) Financial Data
Rhythm Pharmaceuticals Inc. has a market capitalization of $7.54B with a P/E ratio of -34.6x. The company generates $217.16M in trailing twelve-month revenue with a -93.3% profit margin.
Revenue growth is +83.8% quarter-over-quarter, while maintaining an operating margin of -87.1% and return on equity of -101.2%.
Valuation Metrics
Market Cap
$7.54B
Enterprise Value
$7.25B
P/E Ratio
-34.6x
PEG Ratio
-14.0x
Price/Sales
34.2x
Growth & Margins
Revenue Growth (YoY)
+83.8%
Gross Margin
+88.1%
Operating Margin
-87.1%
Net Margin
-93.3%
EPS Growth
+83.8%
Financial Health
Cash/Price Ratio
+4.5%
Current Ratio
4.2x
Debt/Equity
47.3x
ROE
-101.2%
ROA
-29.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rhythm Pharmaceuticals Inc. (RYTM) Business Model
About Rhythm Pharmaceuticals Inc.
What They Do
Develops therapies for rare neuroendocrine diseases.
Business Model
The company focuses on developing and commercializing precision therapies for rare conditions related to hyperphagia and severe obesity. It generates revenue primarily through the sales of its lead product, IMCIVREE, which targets specific genetic disorders that cause uncontrollable hunger, providing an alternative to traditional weight-loss treatments.
Additional Information
Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals operates in a niche market that is relatively insulated from the broader weight management drug dynamics. The company aims to fulfill unmet medical needs in the rare disease obesity sector, positioning itself as a leader in this specialized area of pharmaceuticals and biotech.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
414
CEO
Dr. David P. Meeker M.D.
Country
United States
IPO Year
2017
Website
rhythmtx.comRhythm Pharmaceuticals Inc. (RYTM) Latest News & Analysis
Latest News
Quick Summary
Rhythm Pharmaceuticals has published Phase 3 TRANSCEND trial results for setmelanotide, a treatment for acquired hypothalamic obesity, in NEJM. The company focuses on rare neuroendocrine diseases.
Why It Matters
Positive Phase 3 trial results published in a prestigious journal can boost Rhythm Pharmaceuticals' credibility and stock price, signaling potential for market growth and investor returns.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rhythm Pharmaceuticals reported positive interim results from its Phase 2 trial of Setmelanotide for Prader-Willi Syndrome, indicating progress in its clinical development.
Why It Matters
Positive trial results for Rhythm Pharmaceuticals could lead to increased investor confidence and potential stock price growth, reflecting the company's advancement in treating Prader-Willi Syndrome.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Rhythm Pharmaceuticals announced that its experimental drug for Prader-Willi syndrome successfully reduced hunger and resulted in weight loss.
Why It Matters
Rhythm Pharmaceuticals' drug showing efficacy in reducing hunger and weight loss for Prader-Willi syndrome could boost its market potential, impacting stock performance and investor sentiment.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Rhythm Pharmaceuticals (NASDAQ: RGPX) reported that setmelanotide therapy led to significant weight loss at 2.5 years, while bivamelagon therapy showed BMI and hunger reductions at one year.
Why It Matters
Rhythm Pharmaceuticals' positive long-term results for setmelanotide and bivamelagon therapies may enhance market confidence, potentially boosting stock performance and attracting investment interest.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Rhythm Pharmaceuticals (Nasdaq: RYTM) presented new data at the Endocrine Society's Annual Meeting (ENDO 2026) in Chicago, focusing on rare neuroendocrine diseases.
Why It Matters
Rhythm Pharmaceuticals' new data from a major conference could indicate advancements in their treatments, potentially impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Why Is Rhythm Pharma Stock Jumping Today?
1 month ago
Quick Summary
Rhythm Pharmaceuticals (NASDAQ:RYTM) shares rose after the company announced preliminary Phase 2 study results for setmelanotide in Prader-Willi syndrome patients.
Why It Matters
Rhythm Pharmaceuticals' positive Phase 2 study results for setmelanotide may signal potential market success, boosting investor confidence and stock value.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About RYTM Stock
What is Rhythm Pharmaceuticals Inc.'s (RYTM) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Rhythm Pharmaceuticals Inc. (RYTM) has a median price target of $142.00. The highest price target is $159.00 and the lowest is $105.00.
Is RYTM stock a good investment in 2027?
According to current analyst ratings, RYTM has 15 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $109.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RYTM stock?
Wall Street analysts predict RYTM stock could reach $142.00 in the next 12 months. This represents a 29.5% increase from the current price of $109.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rhythm Pharmaceuticals Inc.'s business model?
The company focuses on developing and commercializing precision therapies for rare conditions related to hyperphagia and severe obesity. It generates revenue primarily through the sales of its lead product, IMCIVREE, which targets specific genetic disorders that cause uncontrollable hunger, providing an alternative to traditional weight-loss treatments.
What is the highest forecasted price for RYTM Rhythm Pharmaceuticals Inc.?
The highest price target for RYTM is $159.00 from at , which represents a 45.0% increase from the current price of $109.69.
What is the lowest forecasted price for RYTM Rhythm Pharmaceuticals Inc.?
The lowest price target for RYTM is $105.00 from at , which represents a -4.3% decrease from the current price of $109.69.
What is the overall RYTM consensus from analysts for Rhythm Pharmaceuticals Inc.?
The overall analyst consensus for RYTM is bullish. Out of 5 Wall Street analysts, 15 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $142.00.
How accurate are RYTM stock price projections?
Stock price projections, including those for Rhythm Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:09 PM UTC